- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03073733
Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis Pigmentosa
A Prospective, Multicenter, Randomized, Study of the Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa (RP)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Irvine, California, United States, 92697
- Gavin Herbert Eye Inst, Univ Cal Irvine
-
Los Angeles, California, United States, 90074
- Retina-Vitreous Associates Medical Group
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Ophthalmic Consultants of Boston
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Clinical diagnosis of RP confirmed by ERG and willing to consent to mutation typing, if not already done Best corrected visual acuity (BCVA) 20/80 or worse and no worse than 20/800 Adequate organ function and negative infectious disease screen Female of childbearing potential must have negative pregnancy test and be willing to use medically accepted methods of contraception throughout the study
Exclusion Criteria:
Eye disease other than RP that impairs visual function Pseudo-RP, cancer-associated retinopathies History of malignancy or other end-stage organ disease, or any chronic disease requiring continuous treatment with system steroids, anticoagulants or immunosuppressive agents Known allergy to penicillin or streptomycin Treatment with corticosteroids or any investigational or neuroprotectant therapy within 90 days of enrollment Cataract surgery within 3 months prior to enrollment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Test (jCell injection) dose level 1
single intravitreal injection of 3.0 x 10e6 human retinal progenitor cells into the eye with the poorest visual acuity or, if vision is comparable in both eyes, the non-dominant eye
|
live suspension of 3.0 or 6.0 x 10e6 human retinal progenitor cells (hRPC) suspended in clinical grade medium injected intravitreally under local anesthesia
Other Names:
|
Other: Sham treated Control
a mock injection will be performed on the eye with the poorest vision in each Control subject (designated as the "study eye")
|
pressing the hub of a syringe with no needle against the eye to mimic intravitreal injection
|
Experimental: test (jCell injection) dose level 2
single intravitreal injection of 6.0 x 10e6 human retinal progenitor cells into the eye with the poorest visual acuity or, if vision is comparable in both eyes, the non-dominant eye
|
live suspension of 3.0 or 6.0 x 10e6 human retinal progenitor cells (hRPC) suspended in clinical grade medium injected intravitreally under local anesthesia
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Best Corrected Visual Acuity (BCVA)
Time Frame: 12 months
|
Mean change in BCVA in study eye from baseline to month 12 as assessed by E-ETDRS in ITT population.
A letter score is used to compare change over time, with a higher number of letters representing better visual function, and a lower number of letters representing worse visual function.
For example, 85 letters is equivalent to 20/20 visual acuity and 5 letters is equivalent to 20/800 visual acuity.
A change value is derived for each subject by taking the letter score at 12 months and subtracting the letter score at baseline.
A mean of all change values is then calculated for each arm.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Contrast Sensitivity (CS) at 1.0 CPD
Time Frame: 12 months
|
Assessment of the ability to detect changes in shades of grey, as measured with a vertical striped pattern that varies in width (cycles per degree or CPD); CS thresholds are created by taking the mean of multiple trials at each pattern width.
A CS curve is created using a minimum of three pattern widths, one at the subject's peak or highest sensitivity, and then one larger and smaller pattern width on either side of the peak.
For example, if a subject's CS peak appears to be at 2.0 CPD, then additional testing occurs at 1.0 and 4.0 CPD.
RP patients have suppressed CS curves and the most common pattern widths are at 0.5, 1.0, 2.0, and 4.0 CPD.
Severely impaired subjects (e.g., BCVA < 20/400) usually have flat curves with low values (e.g., 1.28), while in mildly impaired RP subjects the values can be higher (e.g., 7.12), but are rarely near normal.
These data represent mean change in CS from baseline to 12 months, with greater values representing greater improvement in visual function.
|
12 months
|
Kinetic Visual Field (KVF)
Time Frame: 12 months
|
Mean change in total area (degrees squared) of all islands of vision from baseline to 12 months.
|
12 months
|
Low Luminance Mobility Test (LLMT)
Time Frame: 12 months
|
The LLMT identifies the performance of RP patients as they walk along an indoor pathway of arrows and obstacles at varying lighting levels.
The Critical Illumination Level (CIL) is the light level below which the patient has a markedly slower pace and more errors than all light levels above (brighter than) that point.
The LLMT uses light levels that go from very dim (0.12 lux) to a bright indoor room (500 lux), with evenly spaced increments that increase light by doubling the brightness of the room from the prior level.
These evenly spaced light levels have been converted to a scale score to enable easier calculation of change scores.
The dimmest light level of 0 lux (completely dark room) corresponds to a scale score of 13, whereas the brightest light level of 500 lux corresponds to a scale score of 0. A positive scale score change from baseline to 12 months represents improvement in low light vision, whereas a negative scale score change represents a decline in low light vision.
|
12 months
|
Low Vision Functional Questionnaire (Visual Ability)
Time Frame: 12 months
|
The VA LV VFQ-48 (VFQ) is used to capture changes in patients' self-reporting of their difficulty with reading, mobility and performing other daily living activities affected by visual impairment.
There are 4 scales on the VFQ including Visual Information, Reading, Visual Motor, and Mobility.
A fifth value, Visual Ability, is an aggregate score of the 4 scales, measured in units called logits, and is calculated for each person based on item weighting using Raasch analysis.
Visual Ability is used broadly to represent changes in subject-reported outcomes from visit to visit.
Higher positive values on the Visual Ability score represent better function and less impairment, whereas lower or negatives scores represent worse function or more impairment.
Change in the Visual Ability scale on the VFQ is calculated by taking a subject's score at 12 months and subtracting from it the baseline score.
|
12 months
|
Safety of Intravitreal Injection of Retinal Progenitor Cells (RPC)
Time Frame: 12 months
|
Assessed by treatment emergent adverse events, immunogenicity and safety visual assessments
|
12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Barruch Kuppermann, MD, UCI
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- JC-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Retinitis Pigmentosa
-
MeiraGTx UK II LtdSyne Qua Non Limited; Bionical EmasCompletedGene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR)X-Linked Retinitis PigmentosaUnited Kingdom, United States
-
Oslo University HospitalRecruitingRetinitis Pigmentosa | Retinitis Pigmentosa 11Norway
-
Jinnah Burn and Reconstructive Surgery Centre,...The Layton Rahmatullah Benevolent Trust (LRBT) Free Eye Hospital, Township... and other collaboratorsRecruitingRetinitis Pigmentosa (RP)Pakistan
-
AbbVieActive, not recruitingAdvanced Retinitis PigmentosaUnited States
-
jCyte, IncCalifornia Institute for Regenerative Medicine (CIRM)CompletedRetinitis Pigmentosa (RP)United States
-
Janssen Research & Development, LLCJanssen Research & Development, LLCActive, not recruitingX-Linked Retinitis PigmentosaBelgium, Canada, United States, Israel, United Kingdom, Spain, Denmark, France, Italy, Netherlands, Switzerland
-
Janssen Research & Development, LLCActive, not recruitingX-Linked Retinitis PigmentosaUnited States, United Kingdom
-
GenSight BiologicsRecruitingNon-syndromic Retinitis PigmentosaUnited States, France, United Kingdom
-
Janssen Research & Development, LLCJanssen Research & Development, LLCActive, not recruitingX-Linked Retinitis PigmentosaUnited States, Canada, Israel, United Kingdom, Spain, Denmark, France, Belgium, Italy, Netherlands, Switzerland
-
BiogenCompletedX-Linked Retinitis PigmentosaUnited States, United Kingdom
Clinical Trials on human retinal progenitor cells
-
ReNeuron LimitedActive, not recruitingRetinitis PigmentosaUnited States, United Kingdom, Spain
-
jCyte, IncCalifornia Institute for Regenerative Medicine (CIRM)CompletedRetinitis Pigmentosa (RP)United States
-
jCyte, IncCalifornia Institute for Regenerative Medicine (CIRM)CompletedRetinitis PigmentosaUnited States
-
The First Affiliated Hospital with Nanjing Medical...UnknownMacular Degeneration | Age Related Macular Degeneration | AMDChina
-
Eyecure Therapeutics Inc.Beijing Tongren HospitalUnknownLeber Congenital Amaurosis, Retinitis PigmentosaChina
-
Institute of Biophysics and Cell Engineering of...Belarusian State Medical UniversityEnrolling by invitationAge-Related Macular DegenerationBelarus
-
Cellerant TherapeuticsDepartment of Health and Human ServicesCompletedLymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma | Plasma Cell NeoplasmUnited States
-
Astellas Institute for Regenerative MedicineEnrolling by invitationMacular Degenerative DiseaseUnited Kingdom, United States
-
Navy General Hospital, BeijingDaping Hospital and the Research Institute of Surgery of the Third Military... and other collaboratorsUnknownHypoxic-Ischemic EncephalopathyChina
-
Cellular Biomedicine Group Ltd.RenJi Hospital; Huashan Hospital; Second Affiliated Hospital, School of Medicine... and other collaboratorsCompletedKnee OsteoarthritisChina